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Many vector-borne pathogens evade clearance via rapid variation in their immunogenic surface
expressed proteins. This is exempliﬁed by Anaplasma marginale, a tick-borne bacterial pathogen that
generates major surface protein 2 (Msp2) variants to provide for immune escape and allow long-term
pathogen persistence. In contrast to persistence following infection, immunizationwith a surface protein
complex, which includes Msp2, induces a response that prevents infection upon challenge. We hypothe-
sized that the immune response induced by immunization altered the anti-Msp2 antibody repertoire
as compared to that induced during infection, shifting the immune response toward conserved and
thus broadly protective epitopes. The antibody response to the conserved (CR) and hypervariable (HVR)
regions encoded by the full set of msp2 variant alleles was determined for immunized animals prior to
challenge and non-immunized, infected animals. While both groups of animals had a similar antibody
repertoire in terms of breath andmagnitude, the titers to theMsp2CRwere strongly correlated (p<0.005)
with control of bacteremia only in the infected animals. Among the immunized animals, there was no
correlation between the breadth or magnitude of the anti-Msp2 antibody response and either complete
protection from infection or control of bacteremia. This is consistent with separate immunologic mecha-
nisms being responsible for control of bacteremia in infected animals as compared to immunized animals
and suggests that conserved outer membrane proteins other than Msp2 are responsible for the complete
ing c
 clearance observed follow
. Introduction
Infection with many vector-borne pathogens including Theile-
ia spp., Anaplasma spp., Babesia spp., Borrelia spp., and Plasmodium
pp. results in long-term persistent infection due to the pathogen’s
bility to evade the host immune response. This ability is in large
art due to generation of outer membrane protein antigenic vari-
nts. For example, infection with Anaplasma marginale, a bacterial
athogen of cattle, generally results in life-long persistence in the
ammalian host. Persistence is attributed primarily to rapid shifts
n the surface coat structure and speciﬁcally variation in the highly
mmunogenic major surface protein 2 (Msp2). The expressed copy
f Msp2 is composed of a central hypervariable region that is
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ﬂanked by highly conserved regions (Fig. 1a and b). The variation is
generated by gene conversion in which one of multiplemsp2 donor
alleles is recombined into a single, operon-linked expression site
[1–3]. The donor alleles have 5′ and 3′ regions which are identi-
cal to the expression site copy and ﬂank a unique allele-speciﬁc
hypervariable domain [1,4]. These donor alleles are termed func-
tional pseudogenes as their 5′ and 3′ regions are truncated, they
lack the function elements for in situ transcription, and are only
expressed following recombination into the single expression site
[1,4].
During infection, Msp2 represents dominant antigens recog-
nized by sera from cattle infected with A. marginale. The anti-Msp2
speciﬁc antibody response is predominantly directed toward the
hypervariable region rather than the ﬂanking conserved regions
[5,6]. However, the hypervariable region of newly emergent vari-
ants is not recognizedbyexistingantibody [7,8]. Thus, generationof
Open access under CC BY license.Msp2 variants allows for immune escape and long-term pathogen
persistence [8,9]. In contrast to infection, where clearance does not
occur, immunization with either puriﬁed A. marginale outer mem-
branes or cross-linked outermembrane protein complexes induces
complete protection against infection in 40–70% of vaccinees, and
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Fig. 1. The circular genome of the St. Maries strain of A. marginale (a) has one Msp2
expression site (ES), and ﬁve unique Msp2 pseudogenes which serve as donors for
antigenic variation. Two of the Msp2 pseudogenes are duplicated (P1 and G11, 2
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Table 1
Amino acid sequence of the peptides representing the conserved expression site
domains of Msp2.
Locus Peptides Amino acid sequence
Expression
site
N-
terminal
domain
P1 MSAVSNRKLPLGGVLMALVAAVAPIHSLLA
P2 AVAPIHSLLAAPAAGAGAGGEGLFSGAGAG
P3 EGLFSGAGAGSFYIGLDYSPAFGSIKDFKV
P4 AFGSIKDFKVQEAGGTTRGVFPYKRDAAGR
P5 FPYKRDAAGRVDFKVHNFDWSAPEPKISFK
P6 SAPEPKISFKDSMLTALEGSIGYSIGGARV
P7 IGYSIGGARVEVEVGYERFVIKGGKKSNED
P8 IKGGKKSNEDTASVFLLGKELAYDTARGQV
P9 LAYDTARGQVDRLAAALGKMTKGEAKRWG
Expression
site
P10 VAGAFARAVEGAEVIEVRAIGSTSVMLNAC
P11 GSTSVMLNACYDLLTDGIGVVPYACAGIGG
P12 VPYACAGIGGNFVSVVDGHINPKFAYRVKA
P13 NPKFAYRVKAGLSYALTPEISAFAGAFYHKnd 3H1) as indicated by matching colors. A linear depiction of the Msp2 expression
ite illustrates the source of variability within the Msp2 expression site (b). 30-
er peptides representing the CR and all possible pseudogene segments (c) were
onstructed and used to map the anti-Msp2 antibody response in this study.
rotection against anemia and high-level bacteremia in nearly all
nimals [7,10,11]. Protection correlates with high IgG antibody
iters against surface-exposed polypeptides, including Msp2 [7].
hile protection associates with the IgG response to outer mem-
rane proteins, the speciﬁc epitope targets and characteristics of
his protective immune response remain unknown. In the experi-
ents reported here we investigated the breadth and magnitude
f the anti-Msp2 antibody response associated with the control
f bacteremia in infection, and in the prevention of infection and
ontrol of bacteremia in immunized animals.
The ﬁrst goal of these experiments was to determine if
mmunization altered the magnitude or epitope speciﬁcity of
he anti-Msp2 responses as compared to infection; speciﬁcally
hether immunization as compared to infection shifted the anti-
ody response, in terms of the breadth or magnitude, toward
he conserved regions of Msp2. This immunity against conserved
egion epitopes could prevent immune escape of new variants
nd result in the clearance observed following challenge of immu-
ized animals but not during natural or experimental infection.
he second goal of these experiments was to determine if the
readth or magnitude of the anti-Msp2 antibody response corre-
ated with control of bacteremia in infected animals or prevention
r control of bacteremia in immunized animals. To address theseC-
terminal
domain
P14 SAFAGAFYHKVLGDGDYDELPLSPISDYTG
P15 PLSPISDYTGTAGKNKDTGIASFNFAYFGG
P16 TAGKNKDTGIASFNFAYFGGELGVRFAF
questions, animals were immunized with puriﬁed outer mem-
branes or cross-linked surface proteins from the St. Maries strain
of A. marginale, and the resulting speciﬁc antibody responses to
the hypervariable (HVR) and conserved (CR) regions of Msp2 were
mapped and titered. Vaccinees were then challenged with the
homologous strain of A. marginale. Importantly, the St. Maries
strain, for which the complete genome sequence is available, was
used in these experiments, thus allowing mapping of the Msp2
expressed variants to their original donor pseudogene alleles,
analysis of all possible combinations of the HVR, and comprehen-
sive testing of the epitope speciﬁcity induced by immunization
versus infection.
2. Methods
2.1. Immunization and challenge
The immunization and challenge have been previously reported
in detail [11]. Brieﬂy, two groups of ﬁve calves each were immu-
nized 5 times at 3-week intervals with approximately 35g of
either A. marginale outer membranes or protein complexes sus-
pended in 1mg of saponin in a total volume of 1ml administered
subcutaneously. The third group of ﬁve calves was similarly immu-
nized on the same schedule using only adjuvant. Four months after
the last immunization, all calves were challenged intravenously
with approximately 1×104 A. marginale (St. Maries strain) in 1ml
Hank’s balanced salt solution. Starting 10 days post-challenge, the
packed cell volume and bacteremia, as deﬁned by the percent of
infected erythrocytes, were determined daily for all the animals.
2.2. PCR to conﬁrm infection status
PCR was used to conﬁrm the lack of infection in the four chal-
lenged vaccinees that did not develop microscopically detectable
bacteremia based on daily blood smear examination. DNA was iso-
lated fromwhole blood using a PuregeneDNA isolation kit (Qiagen,
Valencia CA). Primers that speciﬁcally amplify msp5, a single copy
gene, were used to detect A. marginale, as previously described in
detail [12,13]. Ampliﬁcation was performed in 50l volume with
35 cycles of melting at 94 ◦C for 15 s, annealing at 65 ◦C for 58 s, and
extension for 71 s at 72 ◦C.2.3. Measurement of segment speciﬁc antibodies
All conserved (Table 1) and hypervariable (Table 2) regions of
Msp2 in the St. Maries strain were represented by the design and
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Table 2
Pseudogene designations of amino acid sequence of oligopeptides representing the
complete HVR repertoire of Msp2.
Pseudogene donor locus Peptides Amino acid sequence
1 I.1a TKSEAKKWGNAIESATGTTSGDELSKKVCG
I.2 GDELSKKVCGKGTTSGNQCGVNATSGSTNN
I.3 VNATSGSTNNGKLSTVFNTDGAEAISSMDT
I.4 GAEAISSMDTTASGTSNTISLQGMAGNINS
2 I.1a TKSEAKKWGNAIESATGTTSGDELSKKVCG
II.2 GDELSKKVCGKGEGSNGTKKCGTTDSTATT
II.3 CGTTDSTATTKISEVFTEGTDTLLSVEGNK
II.4 DTLLSVEGNKDTINLQGMANNINNLSKEDK
P1 III.1 TKGEAKKWGNAVENATNGDKVSQNVCKGTG
III.2 VSQNVCKGTGSTGSSGNKCGTTDSTATTKI
III.3 TTDSTATTKISAVFTEDAAAQLSTMDNTTI
E6/F7 IV.1 TKGEAKKWGTTVEAATNGQTVSQKVCGNGT
IV.2 VSQKVCGNGTGSSGSNCGKNTTDSTNNNGK
IV.3 TTDSTNNNGKITQAFTADSDTTLLSAESSN
IV.4 TTLLSAESSNISTSGMATNINGLSKEEKAV
9H1 V.1 TKSEAKKWGNAIESATGTTNGEKVSQKVCG
V.2 GEKVSQKVCGNGTGSSGTQCGKNSGDTNGS
V.3 GKNSGDTNGSSTTQHKISAVFTDEATLLSA
V.4 FTDEATLLSAAGDTINTTGMAGNINSLTKD
H
s
a
i
w
d
w
b
c
c
d
i
peptides and14of the 18HVRpeptides, giving a CRbreadth score of
T
Ta Pseudogene 1 and pseudogene 2 encode the identical N-terminal 30 amino acid
VR oligopeptide segment.
ynthesis of 30-mer, overlapping peptides (Fig. 1) [5,6]. Sera from
ll animals obtained prior to immunization, 42 days after the last
mmunization, and 45 days after challenge with live organisms
ere tested. Enzyme-linked immunosorbent assays (ELISA) were
one to map the anti-Msp2 antibody response. Immulon-II 96-
ell plates were coated with 1g of peptide per well in coating
uffer (50mM Na2CO3, pH 9.6) overnight at 4 ◦C, washed with PBS
ontaining 0.05% (vol/vol) Tween20, and then blocked with PBS
ontaining 5% (wt/vol) milk and 0.05% (vol/vol) Tween20 for 1h. To
etermine the end-point titers, sera were diluted starting at 1:10
n blocking buffer. Dilutions were doubled until a signal was no
able 3
he number of peptides and mean titers of the total IgG anti-Msp2 speciﬁc antibody resp
Immunogen Animal ID Immunizeda
CR
# peptides recognizedb Mean (Max) titer
Complexes 5933 6 145 (640)
Complexes 5961 2 60 (640)
Complexes 5972 1 10 (10)
Complexes 5946 4 210 (640)
Complexes 5952 5 232 (640)
Mean 2.8 131
Outer membranes 5953 3 440 (640)
Outer membranes 5966 2 45 (80)
Outer membranes 5978 3 30 (40)
Outer membranes 5982 1 320 (320)
Outer membranes 5975 1 20 (20)
Mean 2.0 171
Infectede
Adjuvant 5969 2 30 (40)
Adjuvant 5967 3 30 (40)
Adjuvant 5958 1 80 (80)
Adjuvant 5979 3 120 (320)
Adjuvant 5974 2 165 (320)
Mean 2.2 85
a Speciﬁc antibody response measured after the ﬁnal immunization and prior to challe
b The number of peptides recognized from either the CR or HVR at a 1:10 serum dilutio
c The mean of the titers for all peptides recognized by each serum sample. The maximu
d Protected from infection as deﬁned by negative PCR and repeated negative blood sme
e Speciﬁc antibody response measured 45 days after infection with A. marginale. (2010) 3741–3747 3743
longer detected or a dilution of 1:20,480 was reached. Titers were
reported as the reciprocal of the last dilution in which antibody
binding was detected. Fifty l of each diluted serum sample were
added to each well in triplicate. Following washing, 50l of 1:500
dilution of recombinant protein G-horseradish peroxidase (Zymed,
Carlsbad, CA), to detect IgG binding, were added per well, and
the plates incubated for 1h at room temperature. After additional
washes, binding of protein G to IgG was detected using Sureblue
microwell peroxidase substrate (Kirkegaard and Perry Laborato-
ries, Gaithersburg,MD) at 100l/well for 15min. and stoppedwith
100l of 1% hydrochloric acid. The optical density at 450nm was
determined. Positive binding was statistically deﬁned as exceeding
the mean plus 2 standard deviations of the OD450 of preimmune
serum from the same animal for the speciﬁc peptide, exceeding
2 times the absolute mean value of OD450 of the test serum with
negative control peptide P1, and greater than the mean plus 2 stan-
dard deviations of the OD450 for a speciﬁc peptide from all control
animals that received only adjuvant.
2.4. Determination of breadth and titer scores
To evaluate and compare the number of Msp2 epitopes recog-
nized, breadth scores and mean titers were determined for each
serum sample. To establish a breadth score, one point was given
for each peptide recognized at a serum dilution of ≥1:10. All of the
points for each conserved region peptide and all of the points for
each HVR peptide were summed separately. In the order to com-
pare the breadth scores between the CR and HVR peptides, the
breadth scorewas divided by the number of peptides in each group.
For example, animal 5933 had antibody recognizing 6 of the 15 CR0.40 and a HVR breadth score of 0.78 (Table 3). To establish a mean
titer for a serum sample, the reciprocal of the end-point dilution for
each peptide was summed and divided by the number of peptides
recognized by that particular serum sample. The titer scores to the
onse after immunization and after challenge.
Bacteremia
HVR
c # peptides recognized Mean (Max) titer Max. % infected RBCs
14 374 (1280) 4.5%
7 277 (1280) 3.4%
12 32 (80) 2.7%
13 222 (640) Protectedd
12 225 (640) Protected
11.6 226
16 338 (1280) 6.4%
12 43 (160) 2.4%
14 40 (40) 1.7%
12 205 (320) Protected
8 330 (640) Protected
12.4 191
16 365 (1280) 31.0%
12 1030 (5120) 19.0%
10 412 (1280) 10.8%
15 251 (1280) 10.3%
11 470 (1280) 5.3%
12.8 506
nge.
n.
m titer for each serum sample is reported in parentheses.
ars.
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Fig. 2. Comparison of the anti-Msp2 antibody response in animals infected with A.
marginale and vaccinees. The antibody response speciﬁcally targeting the CR and
HVR of Msp2 was determined using peptides representing each region of Msp2 in
ELISAs. (a) The breadth score represents the mean number of peptides recognized
by each animal at a ≥1:10 serum dilution. The mean± SD for each group is reported
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Fig. 3. Comparison between the breadth of the anti-Msp2 antibody response and
bacteremia in A. marginale infection. Bacteremia, as represented by the percent of
infected erythrocytes, was determined by daily counting of A. marginale inclusion
bodies in Giemsa stained blood smears. The antibody response speciﬁcally targetingbove each column. (b) Themean titer to the CR andHVR for each serum samplewas
etermined by summing the reciprocal dilutions of all end-point titers and dividing
y the total numberof peptides recognizedat a≥1:10 serumdilution. Themean± SD
or each group is reported above each column.
R and HVR region peptides were determined separately. Corre-
ations were determined by calculating the Spearman rank order
orrelation coefﬁcient using SAS version 9.1.
. Results
.1. Does immunization shift the antibody response toward the
onserved regions of Msp2?
To address this question, the breadth and magnitude of the
ntibody response to all regions of Msp2 were compared in immu-
ized animals and non-immunized, infected animals at the time of
ontrol of the initial bacteremia. Regardless of the treatment, the
readth scores to the HVR peptides were higher than the CR pep-
ides (Fig. 2a). For example, the immunized animals had a mean
readth score of 0.19±0.12 for the CR peptides and a score of
.67±0.15 for the HVR peptides; while the infected animals had
breadth score of 0.15±0.06 for the CR peptides and 0.71±0.14
or the HVR peptides.the CR and HVR of Msp2 was determined using peptides representing each region
of Msp2 in ELISAs. The breadth score represents the mean number of peptides rec-
ognized by each animal at a ≥1:10 serum dilution. Spearman rank order correlation
coefﬁcient is reported.
The breadth scores to the CR peptides were slightly higher
in the immunized animals (0.19±0.12) than in the infected ani-
mals (0.15±0.06).However, thesedifferenceswerenot statistically
signiﬁcant and are unlikely to be biologically relevant, as they
predominantly represent differences between individual animals,
and are due to the recognition of three additional CR peptides,
P3, P15, and P14. P3 and P15 were recognized by vaccinee 5933.
Although this animal had the highest breadth score (0.40) for
the CR peptides, it also had the second highest bacteremia (4.5%
infected erythrocytes) of the immunized animals (Table 3). P14
was solely recognized by vaccinee 5952. The breadth scores to the
HVR peptides were similar when comparing the immunized and
infected animals,with the scores in the infected animalsmarginally
higher (Fig. 2a). When comparing titers, the immunized animals
had higher titers to the CR of Msp2 than did the infected animals
(Fig. 2b). However, the difference was not statistically signiﬁcant
and was attributed to the variation among individual animals.
The infected cattle had higher titers to the HVR than did the vac-
cinees, however, this was primarily attributed an animal (5967)
with markedly high titers. Similarly, there were no signiﬁcant
differences between the immunized and infected animals when
evaluating the titers to individual peptides (Supplemental Fig. 1).
Due to the wide variation among individuals within a group, we
posed the following question: within a treatment group, is there a
correlation between the control of bacteremia and the breadth or
magnitude of the anti-Msp2 antibody response?
3.2. Does either the breadth or magnitude of the anti-Msp2
antibody response correlate with the control of bacteremia in
infected animals?
Among the animals that were infected, there was no correla-
tion between the breadth scores to either the CR or HVR peptides
and bacteremia (Fig. 3). For example, one of the animals (5969)
with the highest total breadth (including both the HVR and CR)
score also had the highest bacteremia (31%). In contrast, there was
a strong inverse correlation between bacteremia and titers to the
CR (Fig. 4a), but not the HVR (Fig. 4b), of Msp2. Those animals with
S.M. Noh et al. / Vaccine 28 (2010) 3741–3747 3745
Fig. 4. Comparison between the magnitude of the anti-Msp2 antibody response to
theCR (a) andHVR (b) andbacteremia inA.marginale infection. Bacteremia, as repre-
sented by the percent of infected erythrocytes, was determined by daily counting of
A
d
r
a
h
r
3
a
i
s
i
a
t
c
n
a
Fig. 5. Comparison between the breadth of the antibody response to Msp2 and bac-
teremia following challenge in vaccinees. Bacteremia, as represented by the percent
of infected erythrocytes, was determined by daily counting of A. marginale inclusion
bodies in Giemsa stained blood smears. The antibody response speciﬁcally targeting. marginale inclusion bodies in Giemsa stained blood smears. The mean titers were
etermined by summing the reciprocal of the end-point dilution for each peptide
ecognized by a serum sample and dividing by the number of peptides recognized
t ≥1:10 dilution. Spearman rank order correlation coefﬁcient is reported.
igher titers to the CR had lower levels of bacteremia (Spearman
ank correlation coefﬁcient =−0.97, p≤0.005).
.3. Does either the breadth or magnitude of the anti-Msp2
ntibody response correlate with protection from infection in
mmunized animals?
To address this question, only the immunized animalswere con-
idered. Because IgG2 levels have been associated with protection
n immunized animals, both total IgG and IgG2 anti-Msp2 speciﬁc
ntibody to each region of Msp2 were measured [10]. The animals
hat did not develop infection (protection from infection) were
ompared to those that developed bacteremia. Among the immu-
ized animals, when measuring total IgG, the breadth scores to CR
nd HVR peptides were similar when comparing the animals thatthe CR and HVR of Msp2 was determined using peptides representing each region
of Msp2 in ELISAs. The breadth score represents the mean number of peptides rec-
ognized by each animal at a ≥1:10 serum dilution. Spearman rank order correlation
coefﬁcient is reported.
were protected from infection to those that developed bacteremia
(Fig. 5). For example, two of the animals with the lowest breadth
score (0.07) to the CRpeptideswere protected from infection. Addi-
tionally, there were also no differences when comparing the total
breadth score, which included the combined total IgG response to
the both the CR and the HVR of Msp2. Findings were similar when
measuring IgG2 (Supplemental Fig. 2). Two of the animals with
the lowest breadth scores to the CR (<0.1) were protected from
infection. The breadth scores to the HVR were higher, but again,
there was no correlation between protection from infection and
the breadth of the IgG2 speciﬁc responses to the HVR.
There was no correlation between the titers to the CR and pro-
tection from infection when considering either total IgG or IgG2
only (Fig. 6a and Supplemental Fig. 3a). Three of the four animals
that were protected from infection had total IgG CR titer scores
above 200, while the remaining animal had a score of 20. The IgG2
titers scores to the CR varied from 0 to 160, while the range of
scores in animals protected from infection varied from 18 to 160
(Supplemental Fig. 3a). Similarly, therewas no correlation between
protection from infection and titers to the HVR of Msp2 when con-
sidering either total IgG or IgG2 (Fig. 6b and Supplemental Fig. 3b).
However, unlike the highly variable response to the CR, animals
that were protected from infection had mid-range to high total
IgG titers to the HVR peptides (205–330). Vaccinees that devel-
oped relatively high levels of bacteremia also had titers in this
range. Among the animals that developed bacteremia, there was a
trend toward vaccineeswith high total IgG titers also having higher
bacteremia.
4. Discussion
All groups of animals, including those that were infected, those
that were immunized and protected from high-level bacteremia,
and those that were immunized and completely protected from
infection had similar anti-Msp2 antibody responses, in terms of
both breadth and magnitude. Thus, we reject the hypothesis that
immunization alters the anti-Msp2 antibody response as compared
to infection. It is possible that there are variant Msp2 epitopes that
3746 S.M. Noh et al. / Vaccine 28
Fig. 6. Comparison between the magnitude of the anti-Msp2 antibody response
to the CR (a) and HVR (b) and bacteremia in vaccinees following challenge. Bac-
teremia, as represented by the percent of infected erythrocytes, was determined by
daily counting of A. marginale inclusion bodies in Giemsa stained blood smears. The
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infection, and requires years to develop [22,23]. In contrast toean titers were determined by summing the reciprocal of the end-point dilution
or each peptide recognized by a serum sample and dividing by the number of pep-
ides recognized at ≥1:10 dilution. Spearman rank order correlation coefﬁcient is
eported.
e did not assess in these experiments, e.g. highly conformation-
ependent epitopes not represented by the overlapping peptides
r epitopes formed by the junction of two recombined oligopep-
ide segments. However, the length of peptides used in the assays,
0 amino acids, is relevant as this length represents the mean
ligopeptide length encoded by segments recombined into the
xpression site during infection (29±13 amino acids) [14]. Fur-
hermore, Msp2 variable-region epitopes have been shown to be
urface exposed, and development of variant-speciﬁc antibody
s associated with variant clearance during persistent infection
8,12,15]. In addition to the lack of a shift in the breadth or
agnitude of the anti-Msp2 antibody production in response to
mmunization, targeting of speciﬁc CR or HVR epitopes did not
orrelate with protective immunity. One possible exception was
he conserved region epitope P5, which was recognized by four (2010) 3741–3747
of ten of the immunized animals, two of which were protected
from infection. None of the infected animals had antibody to
P5.
Among the infected animals, the anti-Msp2 antibody response
was measured during the control of the initial bacteremic peak.
At this time point, high titers to the CR but not the HVR of Msp2
correlated with control of bacteremia. This was not the case in
immunized animals in which there was no correlation between
the anti-Msp2 antibody response and bacteremia, supporting the
hypothesis that separate immunologic mechanisms control bac-
teremia in infected animals as compared to immunized animals.
Among the immunized animals, there was no correlation between
the breadth or magnitude of the anti-Msp2 antibody response and
protection from infection. Among the animals that developed bac-
teremia in the face of immunization, there was a trend toward the
animals with the highest titers to both the HVR and the CR also
having the highest bacteremia. This was particularly true for the
response to the HVR peptides I.1, III.1, and III.3. The reason for this
is unknown, but helps to emphasize the point, that while immu-
nized animals were better able to control bacteremia as compared
to infected animals, epitopes other than those on Msp2 were likely
responsible for that immunologic control.
A strong antibody response is known to be directed against
Msp2 during acute infection. However, the data presented here
fail to show a relationship between antibody to the HVR and con-
trol of bacteremia in either immunized or infected animals during
acute infection. This was not due to a lack of Msp2 epitopes in the
immunogen as immunization resulted in the production of anti-
body to all possible regions of Msp2, except one, thus we can infer
that the immunogen contained awide variety of theMsp2epitopes.
Additionally, the antibody repertoire did not change signiﬁcantly in
response to infection. Thus, a similar antigenic repertoirewas avail-
able in the immunogen and during infection. These data suggest
that the anti-Msp2 antibody response may be irrelevant during the
control of the initial bacteremia, and are consistentwith previously
reported ﬁndings indicating that animals immunized with Msp2
variants were not protected when challenged with A. marginale
expressing similar variants as those in the immunogen [16].
A theme among antigenically variant organisms is the ability
to establish persistent infection which is generally clinically silent
and characterized by lownumbers of detectable organisms. Impor-
tantly during persistent infection, the adaptive immune response
is able to control, but not clear infection. The inability to clear
the infection is thought to be due to the generation of antigeni-
cally variant surface proteins which escape detection and allow
for a window of pathogen replication [17]. For example, repeated
exposure to Plasmodium falciparum, one of the causative agents of
malaria, results in the development of naturally acquired immu-
nity. In both A. marginale and P. falciparum, control of persistent
infection is thought to be due in part to antibody directed toward
surface expressed variant antigens. In the case of A. marginale, a
temporal relationship exists between clearance of an Msp2 vari-
ant and development of a variant-speciﬁc antibody response [8,9].
Similarly, P. falciparum parasites causing clinical disease express a
PfEMP1 protein to which the patient has no pre-existing antibody;
in response the immune system mounts an antibody response
with speciﬁcity for the expressed protein [18–22]. Thus, it has
been suggested that naturally acquired immunity to P. falciparum
correlateswithgradual acquisitionof anentire repertoire of protec-
tive PfEMP1 antibody characterized by asymptomatic parasitemia,
but does not result in sterile immunity or protection against re-naturally acquired immunity, sterile immunity can be induced by
immunization with irradiated sporozoites in the case of P. falci-
parum, and outer membrane proteins, in the case of A. marginale
[7,10,11,24].
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Thedatapresented in this paper indicate that there is no correla-
ion between the prevention of infection due to immunization and
he antibody response to the highly immunogenic hypervariable
urface protein responsible for immune evasion. Thus, the differ-
ncebetween the evasionof immunity resulting inpersistent infec-
ion and the immunization-induced complete clearance is likely
ue to induction of antibody to conserved proteins that occurs fol-
owing immunization but does not occur during natural infection.
lthough antibody to Msp2 is abundantly produced in response
o immunization, antibodies targeting a wide variety of conserved
roteins have also been identiﬁed [25]. Thus, shifting the immune
esponse toward conserved epitopes that are poorly recognized
uring infection may be the key to effective vaccine development.
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